|
|
|
SKYEPHARMA PLC - AGM RESULTS LONDON, UK, 21 May 2008 - SkyePharma PLC (LSE: SKP) announces the results of the voting by shareholders at the Annual General Meeting held earlier today. All resolutions were passed on a show of hands. Two copies of all resolutions passed will be submitted later today...
Full Coverage:
Skyepharma PLC: Skyepharma PLC - AGM Statement
London, UK--(Marketwire - May 21, 2008) - SKYEPHARMA PLC - AGM RESULTS LONDON, UK, 21 May 2008 - SkyePharma PLC announces the results of the voting by shareholders at the Annual General Meeting held earlier today. All resolutions were passed on a show of hands. Two copies of all resolutions...
SkyePharma PLC announces Succession Plan
Wednesday May 21, 1:59 am ET Succession Plan LONDON, UK, 21 May 2008 - News) will announce that its Chief Executive Officer, Frank Condella, intends to step down from his executive position once the Company has completed its financial restructuring by refinancing or renegotiating its convertible...
SkyePharma PLC announces Succession Plan
Succession Plan LONDON, UK, 21 May 2008 - At its Annual General Meeting later today, SkyePharma PLC (LSE: SKP) will announce that its Chief Executive Officer, Frank Condella, intends to step down from his executive position once the Company has completed its financial restructuring by refinancing...
Skyepharma PLC: SkyePharma PLC announces Succession Plan
London, UK--(Marketwire - At its Annual General Meeting later today, SkyePharma PLC will announce that its Chief Executive Officer, Frank Condella, intends to step down from his executive position once the Company has completed its financial restructuring by refinancing or renegotiating its...
SkyePharma PLC announces Succession Plan
London, UK, May 21 / MARKET WIRE/ -- At its Annual General Meeting later today, SkyePharma PLC (LSE: SKP) will announce that its Chief Executive Officer, Frank Condella, intends to step down from his executive position once the Company has completed its financial restructuring by refinancing or...
Skyepharma PLC announces Research Update (Marketwire)
SkyePharma PLC (LSE:SKP.L - The author of the poster, Dr. Ekkehard Beck, stated "Study results suggest that long term treatment with FlutiformTM 100/10?g and FlutiformTM 250/10?g will be a safe therapy for patients with persistent asthma." The results of this trial will form part of the US New...
Skyepharma PLC announces Research Update
SkyePharma Announces Presentation of FlutiformTM Phase III Safety Study at ATS in Toronto LONDON, UK, 20 May, 2008 - The author of the poster, Dr. Ekkehard Beck, stated "Study results suggest that long term treatment with FlutiformTM 100/10?g and FlutiformTM 250/10?g will be a safe therapy for...
Skyepharma PLC announces Research Update
SkyePharma Announces Presentation of FlutiformTM Phase III Safety Study at ATS in Toronto LONDON, UK, 20 May, 2008 - The author of the poster, Dr. Ekkehard Beck, stated "Study results suggest that long term treatment with FlutiformTM 100/10?g and FlutiformTM 250/10?g will be a safe therapy for...
Skyepharma PLC announces Research Update
LONDON--(Marketwire - May 20, 2008) - SkyePharma Announces Presentation of FlutiformTM Phase III Safety Study at ATS in Toronto LONDON, UK, 20 May, 2008 - SkyePharma PLC (LSE: SKP) today announces the presentation of its Phase III, long-term, open label safety study evaluating FlutiformTM for the...
Skyepharma PLC: Skyepharma PLC announces Research Update
LONDON--(Marketwire - The author of the poster, Dr. Ekkehard Beck, stated "Study results suggest that long term treatment with FlutiformTM 100/10?g and FlutiformTM 250/10?g will be a safe therapy for patients with persistent asthma." The results of this trial will form part of the US New Drug...
Related categories
David Yates, Peter Grant, Canary Wharf, SkyePharma, England, Greater London, United Kingdom, London (England)
International editions
English - US | English - UK | Deutsch | Française | Español | Português | Italiano | Česká | Русский (Russian) | عربي (Arabic) | 中文（简）(Simplified Chinese)Copyright © 2008 Newstin a.s. All rights reserved. 4.2.5,fe-web-4.2.5;commons-4.2.1;api-4.2.1;fe-4.2.3, 10.10.1.29